AE37: a novel T-cell-eliciting vaccine for breast cancer

作者：Sears Alan K; Perez Sonia A; Clifton Guy T; Benavides Linda C; Gates Jeremy D; Clive Kevin S; Holmes Jarrod P; Shumway Nathan M; Van Echo David C; Carmichael Mark G; Ponniah Sathibalan; Baxevanis Constantin N; Mittendorf Elizabeth A; Papamichail Michael; Peoples George E^*

来源：Expert Opinion on Biological Therapy, 2011, 11(11): 1543-1550.

DOI：10.1517/14712598.2011.616889

• AE36 peptide
• AE37 vaccine
• breast cancer
• cancer vaccines
• Ii-Key hybrid
• prostate cancer

Introduction: Immunotherapy, including vaccines targeting the human EGFR2 (HER-2/neu) protein, is an active area of investigation in combatting breast cancer. Several vaccines are currently undergoing clinical trials, most of which are CD8(+) T-cell-eliciting vaccines. AE37 is a promising primarily CD4(+) T-cell-eliciting HER-2/neu breast cancer vaccine currently in clinical trials.
Areas covered: This article reviews preclinical investigations as well as findings from completed and ongoing Phase I and Phase II clinical trials of the AE37 vaccine.
Expert opinion: Clinical trials have shown the AE37 vaccine to be safe and capable of generating peptide-specific, durable immune responses. This has been shown in patients with any level of HER-2/neu expression. Early clinical findings suggest there may be benefit to AE37 vaccination in preventing breast cancer recurrence.

• 出版日期2011-11